EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Costs of integrating hepatitis B screening and antiviral prophylaxis into routine antenatal care in Burkina Faso: Treat all versus targeted strategies

Andréa Gosset iD, Seydou Drabo, Patrizia Carrieri, Abdoul Salam Eric Tiendrebeogo, Jeanne Perpétue Vincent, Yasuhito Tanaka, Roger Sombié, Haoua Tall, Dramane Kania, Sylvie Boyer, Yusuke Shimakawa

International Journal of Gynecology & Obstetrics · 2024

DOI: 10.1002/ijgo.15515 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Gynecology & Obstetrics, 2024. Verfasst von Andréa Gosset und 10 weiteren Autor:innen. Beteiligte Einrichtung: Aix Marseille University, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Marseille…. Hauptthemen laut MEDLINE: Prenatal Care, Pregnancy Complications, Infectious, Tenofovir, Hepatitis B. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ANRS, Japan Society for the Promotion of Science London, Agence Nationale de Recherches sur le Sida et les Hépatites Virales.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Economic feasibility of eliminating mother‐to‐child transmission (MTCT) of hepatitis B virus (HBV) in highly endemic African countries remains uncertain. Prevention of MTCT (PMTCT) involves screening pregnant women for hepatitis B surface antigen (HBsAg), identifying those with high viral loads or hepatitis B e antigen (HBeAg), and administering tenofovir prophylaxis to high‐risk women. We estimated the costs of integrating PMTCT services into antenatal care in Burkina Faso, based on four different strategies to select women for tenofovir prophylaxis: (1) HBV DNA (≥200 000 IU/mL), (2) HBeAg, (3) hepatitis B core‐related antigen rapid diagnostic test (HBcrAg‐RDT) and (4) all HBsAg‐positive women.

Methods

Using a micro‐costing approach, we estimated the incremental economic cost of integrating each strategy into routine antenatal care in 2024, compared to neonatal vaccination alone. Sensitivity analyses explored variations in prevalence, service coverage, test and tenofovir prices.

Results

HBcrAg‐RDT strategy was the least expensive, with a total economic cost of US$3959689, compared to HBV DNA (US$6128875), HBeAg (US$4135233), and treat‐all (US$4141206). The cost per pregnant woman receiving tenofovir prophylaxis varied from US$61.88 (Treat‐all) to US$1071.05 (HBV DNA). The Treat‐All strategy had the lowest marginal cost due to a higher number of women on tenofovir (66928) compared to HBV DNA (5722), HBeAg (10020), and HBcrAg‐RDT (7234). In sensitivity analyses, the treat‐all strategy became less expensive when the tenofovir price decreased.

Conclusion

HBcrAg‐RDT minimizes resource use and costs, representing 0.61% of Burkina Faso's 2022 health budget. This study highlights the potential economic feasibility of these strategies and provides valuable resources for conducting cost‐effectiveness analyses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prenatal CarePregnancy Complications, InfectiousTenofovirHepatitis BInfectious Disease Transmission, VerticalAntiviral AgentsHumansFemaleBurkina FasoPregnancyMass ScreeningHepatitis B e AntigensCost-Benefit AnalysisHepatitis B Surface AntigensAdultDNA, ViralHepatitis B virusViral Load

Stichwörter der Autor:innen

Africacostshepatitis Bmother‐to‐child transmissionscreeningtenofovirtreatment

Substanzen

TenofovirAntiviral AgentsHepatitis B e AntigensHepatitis B Surface AntigensDNA, Viral

Autor:innen und Institutionen

  • Aix Marseille University, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Marseille, France.
  • Laboratoire Mixte International de Vaccinologie (LAMIVAC), Bobo-Dioulasso, Burkina Faso.
  • Institut Pasteur, Université Paris Cité, Unité d'Épidémiologie des Maladies Émergentes, Institut Pasteur, Paris, France.
  • Department of Gastroenterology and Hepatology, Kumamoto University, Kumamoto, Japan.
  • Département d'Hépato-Gastroentérologie, Center Hospitalier Universitaire Yalgado Ouédraogo, Ouagadougou, Burkina Faso.
  • Center Muraz, Institut National de Santé Publique, Bobo-Dioulasso, Burkina Faso.

ORCID-Profile: Andréa Gosset

Förderung

  • ANRS
  • Japan Society for the Promotion of Science London
  • Agence Nationale de Recherches sur le Sida et les Hépatites Virales

Zitieren

APA

Gosset, A., Drabo, S., Carrieri, P., Tiendrebeogo, A. S. E., Vincent, J. P., Tanaka, Y., Sombié, R., Tall, H., Kania, D., Boyer, S., & Shimakawa, Y. (2024). Costs of integrating hepatitis B screening and antiviral prophylaxis into routine antenatal care in Burkina Faso: Treat all versus targeted strategies. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.15515

Vancouver

Gosset A, Drabo S, Carrieri P, Tiendrebeogo ASE, Vincent JP, Tanaka Y, et al. Costs of integrating hepatitis B screening and antiviral prophylaxis into routine antenatal care in Burkina Faso: Treat all versus targeted strategies. International Journal of Gynecology & Obstetrics. 2024. doi:10.1002/ijgo.15515

BibTeX
@article{Gosset2024,
  author = {Gosset, Andréa and Drabo, Seydou and Carrieri, Patrizia and Tiendrebeogo, Abdoul Salam Eric and Vincent, Jeanne Perpétue and Tanaka, Yasuhito and Sombié, Roger and Tall, Haoua and Kania, Dramane and Boyer, Sylvie and Shimakawa, Yusuke},
  title = {Costs of integrating hepatitis B screening and antiviral prophylaxis into routine antenatal care in Burkina Faso: Treat all versus targeted strategies},
  journal = {International Journal of Gynecology & Obstetrics},
  year = {2024},
  doi = {10.1002/ijgo.15515}
}
Kostenlos starten →